# Michael L. Wang

Source: https://onco.cc/people/michael-wang/  
OnCo record `michael-wang` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the ibrutinib and brexucabtagene autoleucel trials that transformed mantle cell lymphoma treatment.

## Summary

Michael Wang was principal investigator of the pivotal trial of ibrutinib in relapsed mantle cell lymphoma, the first BTK inhibitor approval in the disease, and of ZUMA-2, which established brexucabtagene autoleucel CAR-T therapy for relapsed MCL. He led the chemotherapy-free ibrutinib-rituximab WINDOW trials and the SYMPATICO trial of ibrutinib plus venetoclax. He directs the mantle cell lymphoma programme at MD Anderson.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lymphoma; mantle-cell; car-t
- Role: Puddin Clarke Endowed Professor, Department of Lymphoma and Myeloma, MD Anderson Cancer Center
- Specialisms: Mantle cell lymphoma; BTK inhibitors; CAR T-cell therapy; Chemotherapy-free regimens

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Wang%20ML%5BAuthor%5D%20mantle%20cell%20lymphoma

## Connected records

- cancers: [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/), [CD19](https://onco.cc/targets/cd19/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- key papers: [Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma](https://onco.cc/key-papers/paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025/), [Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma](https://onco.cc/key-papers/paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022/), [ZUMA-2: brexu-cel CAR-T for mantle cell lymphoma that has failed BTK inhibitors](https://onco.cc/key-papers/paper-zuma-2-brexu-cel-mantle-cell-nejm-2020/)
- trials: [SHINE](https://onco.cc/trials/shine/), [ZUMA-2](https://onco.cc/trials/zuma-2/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/michael-wang.json